Do peptides help endometriosis?

The short answer

Evidence tier: 1 — ESHRE 2022 guideline, Cochrane reviews and phase 3 RCTs for standard treatments; tier 4–5 for the community-hyped peptides.

Yes, some peptides help endometriosis, but not the ones usually meant by the question. The peptides with real evidence are GnRH agonists such as leuprolide and goserelin. They are approved prescription drugs with decades of randomised trials for endometriosis pain, although a 2023 Cochrane review rated the placebo-controlled evidence as low certainty.

The peptides talked about online, BPC-157, KPV and thymosin alpha-1, have no published endometriosis studies in people or animals. Their anti-inflammatory data come from gut, tendon and immune research. Interest in GLP-1 drugs for endometriosis is growing, but so far it rests on hypotheses, not trials.

Endometriosis care is built around two goals, controlling pain and protecting fertility, and the best treatment depends on which matters more for you right now. That is a conversation for your gynaecologist.

The key points:

• First-line treatments are pain relief, hormonal contraceptives and progestogens. GnRH agonists and antagonists are second-line options.
• Leuprolide and goserelin are true peptides. They reduce pain, but they cause bone loss, so their use is time-limited or paired with "add-back" hormones.
• Elagolix and relugolix combination are oral GnRH antagonists that are not peptides. They have large phase 3 trials behind them.
• No published study has tested BPC-157, KPV or thymosin alpha-1 in endometriosis.
• Hormonal suppression lowers pain but does not improve the chance of pregnancy, and is not given for that purpose.

What is endometriosis, and why is it hard to treat?

Evidence tier: 1 — major reviews and international guideline.

Endometriosis is a long-term condition in which tissue similar to the lining of the womb grows outside it, most often in the pelvis. It affects an estimated 5–10% of women of reproductive age (PMID 33640070). The main problems are painful periods, pelvic pain, pain with sex, and difficulty getting pregnant (PMID 32212520).

The lesions respond to oestrogen, which is why most medical treatments work by lowering oestrogen or blocking its effects. The disease also involves inflammation, new blood-vessel growth and changes in how the nervous system processes pain. That helps explain why hormonal treatment does not work for everyone. Progestins and low-dose contraceptives fail in around a third of women with symptoms (PMID 33640070).

What treatments have strong evidence?

Evidence tier: 1 — ESHRE guideline, Cochrane reviews, phase 3 RCTs and regulator labels.

The ESHRE 2022 guideline makes 109 recommendations. Its main shift was to stop treating laparoscopy as the required route to a diagnosis. Imaging and a clinical diagnosis can now be enough to start treatment, with surgery kept for cases where imaging is negative or treatment fails (Consultant360 summary).

The main options:

Which peptides have real evidence for endometriosis?

Evidence tier: 1 — Cochrane review, FDA and UK labels.

The honest answer to "peptides for endometriosis" is the GnRH agonists. They are man-made versions of the brain's own GnRH peptide. Given continuously, they first stimulate and then shut down the signal to the ovaries, so oestrogen falls to menopausal levels.

• Leuprolide (Lupron Depot 3.75 mg) is FDA-approved to manage endometriosis, "including pain relief and reduction of endometriotic lesions." It causes bone loss, some of which may not reverse. It can be given with norethindrone acetate "add-back" therapy, which is required for any repeat course, and total treatment should not exceed 12 months (Lupron Depot label).
• Goserelin (Zoladex 3.6 mg implant) is licensed in the UK to relieve endometriosis symptoms and shrink lesions. The licence limits treatment to six months, and bone density falls by an average of about 1% per month (Zoladex SmPC).

Common side effects reflect low oestrogen: hot flushes, vaginal dryness, mood changes and bone loss. ESHRE places GnRH agonists as a second-line option after first-line hormonal treatment.

Are elagolix and relugolix peptides?

Evidence tier: 1 — phase 3 RCTs and regulatory approvals.

No. They block the same GnRH receptor but are non-peptide pills, so they do not belong on peptide lists, even though they are often mentioned alongside them.

• Elagolix (Orilissa) was approved by the FDA in 2018 (Bloomberg). In two phase 3 trials, 43–46% of women on the lower dose and 72–76% on the higher dose had a meaningful improvement in period pain at three months, compared with 20–23% on placebo (PMID 28525302).
• Relugolix combination therapy (relugolix with estradiol and norethindrone acetate) helped 75% of women with period pain, compared with 27–30% on placebo, in the SPIRIT 1 and 2 trials. Bone loss was small, under 1% at the spine over 24 weeks (PMID 35717987). It is sold as Myfembree in the US, approved for endometriosis pain in 2022 for up to 24 months (Clinical Trials Arena). In the EU it is sold as Ryeqo, approved in November 2023 for women who have already had medical or surgical treatment (BioSpace).

Do BPC-157 or KPV help endometriosis?

Evidence tier: 5 for endometriosis (no studies); 4 for the underlying anti-inflammatory claims (animal and cell data).

A PubMed search in November 2026 found no endometriosis studies of either peptide, not even in animals. ClinicalTrials.gov also lists none. The claims online are borrowed from other research:

• KPV is a three-amino-acid fragment of alpha-MSH. It reduced gut inflammation in mouse colitis models (PMID 18061177; PMID 28143741). It has not been tested in human trials for any condition.
• BPC-157 has wide animal data on healing. A 2026 systematic review found just three small, poor-quality human studies in total (PMID 42885452).

There is also a biological reason for caution. BPC-157 promotes new blood-vessel growth in animal and cell studies through the VEGFR2 pathway (PMID 27847966), and endometriosis lesions depend on new blood vessels to survive. Whether that matters in practice is unknown, but it means "anti-inflammatory" does not automatically mean "helpful" here.

Neither peptide is approved in the US, EU or UK. In April 2026 the FDA took both off its Category 2 list after the nominations were withdrawn. That did not make them legal to compound (National Law Review). In July 2026 an FDA advisory committee narrowly voted to support compounding both, but the vote is non-binding and neither has been added to the compounding list (AJMC). Grey-market purity is unknown.

Could GLP-1 drugs help endometriosis?

Evidence tier: 4 — one small case-control study and hypothesis papers; no clinical trials.

This is an area of growing interest, not established treatment.

• One 2022 study found lower GLP-1 levels in the pelvic fluid of women with endometriosis (PMID 36142272).
• A 2026 paper proposed tirzepatide as a possible add-on treatment. Its authors say plainly that the idea rests on that single, unreplicated study, and that direct experimental or clinical validation is currently absent (PMID 42449952).
• A search of ClinicalTrials.gov found no registered trials of semaglutide or tirzepatide for endometriosis.

GLP-1 drugs can still be prescribed for their approved uses, such as obesity or diabetes, in women who also have endometriosis. If you are planning a pregnancy, the timing matters. See our GLP-1s and pregnancy planning guide.

What about thymosin alpha-1 and kisspeptin?

Evidence tier: 5 for thymosin alpha-1 in endometriosis (no studies); 4 for kisspeptin (laboratory and tissue research).

Thymosin alpha-1 is an immune-modulating peptide studied mainly in infections and as a support during chemotherapy (PMID 19392576). Endometriosis does involve immune changes, which is where the online interest comes from. But no study has tested thymosin alpha-1 in endometriosis.

Kisspeptin is a real research target, but not as a treatment yet. It sits above GnRH in the reproductive hormone chain. Researchers have found altered kisspeptin and receptor levels in endometriosis tissue (PMID 39768606). A 2026 cell and animal study suggested kisspeptin signalling may reduce lesion cell invasion and blood-vessel growth (PMID 41399389). Because kisspeptin also stimulates the ovaries, injecting it could raise oestrogen, the opposite of what most treatments aim for. It is not approved anywhere.

How do pain and fertility goals change the choice?

Evidence tier: 1 — ESHRE guideline and Cochrane review.

• If pain is the main issue and pregnancy is not a near-term goal, hormonal suppression is the core of treatment, moving to GnRH agonists or antagonists if first-line options fail.
• If you are trying to conceive, every hormonal treatment above, including the GnRH peptides, stops ovulation while you take it. ESHRE strongly recommends against giving hormone suppression after surgery just to improve future pregnancy rates. Surgery and/or assisted reproduction are the routes ESHRE describes for endometriosis-related infertility (PMID 35350465).
• Untested peptides add unknowns when you are trying to conceive. There are no pregnancy safety data for BPC-157, KPV or thymosin alpha-1. See our peptides in pregnancy and breastfeeding guide.

Questions to bring to your gynaecologist:

1. Is pain or fertility my priority for the next one to two years, and how does that change the plan?
2. If first-line treatment has not worked, am I a candidate for a GnRH agonist or an oral antagonist?
3. How will my bone health be protected, and for how long can I stay on treatment?
4. Is there a clinical trial I could join?
5. If I am considering any non-prescribed peptide, what risks would it add?

Limitations of the evidence

Evidence tier: 4–5 — summary of the evidence gaps above.

• Even for GnRH agonists, Cochrane rated the placebo-controlled evidence low certainty.
• No study in people or animals has tested BPC-157, KPV or thymosin alpha-1 in endometriosis; their claims are borrowed from gut, tendon and immune research.
• BPC-157 has only three small, poor-quality human studies for any use, and KPV has none.
• The GLP-1 idea rests on one small, unreplicated case-control study, with no registered trials.
• Kisspeptin data come from cells, tissue and animals only, and none of the untested peptides has pregnancy safety data.

The bottom line

The peptides that help endometriosis are prescription GnRH agonists, backed by decades of trials and limited mainly by low-oestrogen side effects and bone loss. Oral GnRH antagonists work in a similar way but are not peptides. BPC-157, KPV and thymosin alpha-1 have no endometriosis evidence, and GLP-1 drugs and kisspeptin are research questions for now. A gynaecologist who knows your pain pattern and fertility plans is the right person to choose among the proven options.

Related on this site

• BPC-157: animal vs human evidence
• KPV peptide: mechanism and evidence
• Peptides and autoimmune conditions
• GLP-1s, PCOS and fertility
• Kisspeptin and female sexual health
• Peptides and menstrual cycle timing
• Peptides for women: the 2026 guide

References

• Becker CM et al. ESHRE guideline: endometriosis. Hum Reprod Open 2022 — 109 recommendations on diagnosis, pain and infertility. PMID 35350465
• Zondervan KT et al. Endometriosis. N Engl J Med 2020 — clinical review. PMID 32212520
• Taylor HS et al. Endometriosis is a chronic systemic disease: clinical challenges and novel innovations. Lancet 2021 — prevalence and systemic features. PMID 33640070
• Veth VB et al. Gonadotropin-releasing hormone analogues for endometriosis. Cochrane Database Syst Rev 2023 — 72 studies; supersedes the 2010 review; low-certainty evidence. PMID 37341141
• Chen I et al. Progestagens for pain symptoms associated with endometriosis. Cochrane Database Syst Rev 2025 — 33 RCTs. PMID 41065045
• Bafort C et al. Laparoscopic surgery for endometriosis. Cochrane Database Syst Rev 2020 — pain benefit uncertain, pregnancy rates higher. PMID 33095458
• Taylor HS et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med 2017 — Elaris EM-I and EM-II. PMID 28525302
• Giudice LC et al. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain (SPIRIT 1 and 2). Lancet 2022 — phase 3 RCTs. PMID 35717987
• AbbVie. Lupron Depot 3.75 mg prescribing information. — endometriosis indication, add-back required for retreatment, 12-month limit. Label PDF
• AstraZeneca. Zoladex 3.6 mg implant SmPC. — six-month endometriosis limit, bone density. EMC
• Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008 — mouse colitis. PMID 18061177
• Xiao B et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther 2017 — mouse model. PMID 28143741
• Poolton JT et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review. Acta Orthop Belg 2026 — three poor-quality human studies. PMID 42885452
• Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med 2017 — angiogenesis in rats and cells. PMID 27847966
• Krasnyi AM et al. The levels of ghrelin, glucagon, visfatin and GLP-1 are decreased in the peritoneal fluid of women with endometriosis. Int J Mol Sci 2022 — case-control. PMID 36142272
• Jacobsen L et al. Peritoneal incretin deficiency and tirzepatide as a multi-axis adjuvant hypothesis in treatment-refractory endometriosis. Int J Mol Sci 2026 — hypothesis paper. PMID 42449952
• Goldstein AL et al. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther 2009 — review. PMID 19392576
• Meczekalski B et al. Kisspeptin and endometriosis — is there a link? J Clin Med 2024 — narrative review. PMID 39768606
• Kong L et al. Kisspeptins inhibit ectopic endometrial cell invasion and angiogenesis by suppressing PI3K/AKT signaling via CREB5 in endometriosis. Int J Med Sci 2026 — cell and animal data. PMID 41399389